Eleanor Earp
Research Subjects
Eleanor Earp has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
Amer Durrani
6 shared publications- Amit Roshan
Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London, UK
6 shared publications Benjamin A. Hall
6 shared publications- Charlotte King
Wellcome Sanger Institute, Hinxton, UK
6 shared publications - Christopher Bryant
Wellcome Sanger Institute, Hinxton, United Kingdom
6 shared publications - David Fernandez-Antoran
University of Cambridge
6 shared publications
Latest Publications
- Open Access
- 18 July 2023
- Published by Elsevier in JID Innovations
- Vol. 3 (5) , 100213
Reliable Detection of Eczema Areas for Fully Automated Assessment of Eczema Severity from Digital Camera Images
- 18 July 2023
- Published by Elsevier in JID Innovations
- Vol. 3 (5) , 100213
Open AccessReliable Detection of Eczema Areas for Fully Automated Assessment of Eczema Severity from Digital Camera Images
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Selection of Oncogenic Mutant Clones in Normal Human Skin Varies with Body Site
Supplementary Figures S1-S7 and Tables S1 and S2
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Selection of Oncogenic Mutant Clones in Normal Human Skin Varies with Body Site
Supplementary Figures S1-S7 and Tables S1 and S2
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Selection of Oncogenic Mutant Clones in Normal Human Skin Varies with Body Site
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Selection of Oncogenic Mutant Clones in Normal Human Skin Varies with Body Site
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Selection of Oncogenic Mutant Clones in Normal Human Skin Varies with Body Site
Supplementary Figures S1-S7 and Tables S1 and S2
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Selection of Oncogenic Mutant Clones in Normal Human Skin Varies with Body Site
Supplementary Figures S1-S7 and Tables S1 and S2
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Selection of Oncogenic Mutant Clones in Normal Human Skin Varies with Body Site
Skin cancer risk varies substantially across the body, yet how this relates to the mutations found in normal skin is unknown. Here we mapped mutant clones in skin from high- and low-risk sites. The density of mutations varied by location. The prevalence of NOTCH1 and FAT1 mutations in forearm, trunk, and leg skin was similar to that in keratinocyte cancers. Most mutations were caused by ultraviolet light, but mutational signature analysis suggested differences in DNA-repair processes between sites. Eleven mutant genes were under positive selection, with TP53 preferentially selected in the head and FAT1 in the leg. Fine-scale mapping revealed 10% of clones had copy-number alterations. Analysis of hair follicles showed mutations in the upper follicle resembled adjacent skin, but the lower follicle was sparsely mutated. Normal skin is a dense patchwork of mutant clones arising from competitive selection that varies by location.Significance:Mapping mutant clones across the body reveals normal skin is a dense patchwork of mutant cells. The variation in cancer risk between sites substantially exceeds that in mutant clone density. More generally, mutant genes cannot be assigned as cancer drivers until their prevalence in normal tissue is known.See related commentary by De Dominici and DeGregori, p. 227.This article is highlighted in the In This Issue feature, p. 211
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Selection of Oncogenic Mutant Clones in Normal Human Skin Varies with Body Site
Skin cancer risk varies substantially across the body, yet how this relates to the mutations found in normal skin is unknown. Here we mapped mutant clones in skin from high- and low-risk sites. The density of mutations varied by location. The prevalence of NOTCH1 and FAT1 mutations in forearm, trunk, and leg skin was similar to that in keratinocyte cancers. Most mutations were caused by ultraviolet light, but mutational signature analysis suggested differences in DNA-repair processes between sites. Eleven mutant genes were under positive selection, with TP53 preferentially selected in the head and FAT1 in the leg. Fine-scale mapping revealed 10% of clones had copy-number alterations. Analysis of hair follicles showed mutations in the upper follicle resembled adjacent skin, but the lower follicle was sparsely mutated. Normal skin is a dense patchwork of mutant clones arising from competitive selection that varies by location.Significance:Mapping mutant clones across the body reveals normal skin is a dense patchwork of mutant cells. The variation in cancer risk between sites substantially exceeds that in mutant clone density. More generally, mutant genes cannot be assigned as cancer drivers until their prevalence in normal tissue is known.See related commentary by De Dominici and DeGregori, p. 227.This article is highlighted in the In This Issue feature, p. 211
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Selection of Oncogenic Mutant Clones in Normal Human Skin Varies with Body Site
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Selection of Oncogenic Mutant Clones in Normal Human Skin Varies with Body Site
- 1 October 2022
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 47 (10) , 1794-1804
A review of the evidence for Mohs micrographic surgery. Part 2: basal cell carcinoma
Summary: Mohs micrographic surgery (MMS) is considered the gold-standard treatment for basal cell carcinoma (BCC) particularly for sites with a high-risk of incomplete excision such as the central face, for tumours with an aggressive growth pattern and consequent unpredictable subclinical extension and for recurrent tumours. However, the process is more time-consuming than for standard excision (SE), and the magnitude of benefit is uncertain. This article aims to provide a more complete picture of current evidence, including a review of cosmetic outcomes, tissue-sparing ability and cost-effectiveness of MMS. Although robust evidence is lacking, there is a large volume of observational data supporting a low recurrence rate after MMS. The risk of incomplete excision and higher recurrence rate of standard excision favours the use of MMS at high-risk sites. There is some low-certainty evidence that MMS results in a smaller defect size compared with SE, and that incomplete excision with SE results in larger defects. Larger defects may affect cosmetic outcome but there is no direct evidence that MMS improves cosmetic outcome compared with SE. There is conflicting evidence regarding the cost of MMS compared with SE, as some studies consider MMS less expensive than SE and others consider it more expensive, which may reflect the healthcare setting. A multicentre 10-year randomized controlled trial comparing MMS and SE in the treatment of high-risk BCC would be desirable, but is unlikely to be feasible or ethical. Collection of robust registry data capturing both MMS and SE outcomes would provide additional long-term outcomes.
- 1 October 2022
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 47 (10) , 1794-1804
A review of the evidence for Mohs micrographic surgery. Part 2: basal cell carcinoma
Summary: Mohs micrographic surgery (MMS) is considered the gold-standard treatment for basal cell carcinoma (BCC) particularly for sites with a high-risk of incomplete excision such as the central face, for tumours with an aggressive growth pattern and consequent unpredictable subclinical extension and for recurrent tumours. However, the process is more time-consuming than for standard excision (SE), and the magnitude of benefit is uncertain. This article aims to provide a more complete picture of current evidence, including a review of cosmetic outcomes, tissue-sparing ability and cost-effectiveness of MMS. Although robust evidence is lacking, there is a large volume of observational data supporting a low recurrence rate after MMS. The risk of incomplete excision and higher recurrence rate of standard excision favours the use of MMS at high-risk sites. There is some low-certainty evidence that MMS results in a smaller defect size compared with SE, and that incomplete excision with SE results in larger defects. Larger defects may affect cosmetic outcome but there is no direct evidence that MMS improves cosmetic outcome compared with SE. There is conflicting evidence regarding the cost of MMS compared with SE, as some studies consider MMS less expensive than SE and others consider it more expensive, which may reflect the healthcare setting. A multicentre 10-year randomized controlled trial comparing MMS and SE in the treatment of high-risk BCC would be desirable, but is unlikely to be feasible or ethical. Collection of robust registry data capturing both MMS and SE outcomes would provide additional long-term outcomes.
- 1 October 2022
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 47 (10) , 1765-1773
A review of Mohs micrographic surgery for skin cancer. Part 3: Squamous cell carcinoma
This review presents and discusses the evidence for MMS to treat cutaneous squamous cell carcinoma (cSCC). The MEDLINE, Embase and Cochrane databases were searched; 39 papers were identified for recurrence and 2 papers for cost-effectiveness. We included all clinical trials and observational studies, including retrospective reports, and excluded editorials and systematic reviews or meta-analyses. We categorized the evidence under the following headings: tumour recurrence, specific site outcomes (ear, lip, scalp and periocular), cSCC with perineural invasion, and cost-effectiveness. Although there are many observational studies indicating the potential benefits of MMS in the management of certain cSCCs, no randomized controlled trials (RCT) were identified. The evidence from comparitor studies suggests that MMS has a lower recurrence rate than that of other treatments for cSCC, including standard excision. Many studies identified were single-armed, but did demonstrate a low to very low recurrence rate of cSCC following MMS. A single recent study suggests MMS for intermediate cSCC is highly cost-effective compared with wide local excision when all-in costs are considered. Since the overall quality of included studies was mixed and highly heterogeneous, further methodologically robust studies with comparator arms or comprehensive long-term registry data would be valuable. It would be ideal to employ a definitive multicentre RCT but given the evidence to date and multiple advantages to MMS, the lack of clinical equipoise makes this difficult to justify. Comparison with current modalities would likely not be ethical/achievable on a like-for-like basis given MMS provides 100% margin assessment, enables histological clearance prior to reconstruction, and minimizes the removal of uninvolved tissue.
- 1 October 2022
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 47 (10) , 1765-1773
A review of Mohs micrographic surgery for skin cancer. Part 3: Squamous cell carcinoma
This review presents and discusses the evidence for MMS to treat cutaneous squamous cell carcinoma (cSCC). The MEDLINE, Embase and Cochrane databases were searched; 39 papers were identified for recurrence and 2 papers for cost-effectiveness. We included all clinical trials and observational studies, including retrospective reports, and excluded editorials and systematic reviews or meta-analyses. We categorized the evidence under the following headings: tumour recurrence, specific site outcomes (ear, lip, scalp and periocular), cSCC with perineural invasion, and cost-effectiveness. Although there are many observational studies indicating the potential benefits of MMS in the management of certain cSCCs, no randomized controlled trials (RCT) were identified. The evidence from comparitor studies suggests that MMS has a lower recurrence rate than that of other treatments for cSCC, including standard excision. Many studies identified were single-armed, but did demonstrate a low to very low recurrence rate of cSCC following MMS. A single recent study suggests MMS for intermediate cSCC is highly cost-effective compared with wide local excision when all-in costs are considered. Since the overall quality of included studies was mixed and highly heterogeneous, further methodologically robust studies with comparator arms or comprehensive long-term registry data would be valuable. It would be ideal to employ a definitive multicentre RCT but given the evidence to date and multiple advantages to MMS, the lack of clinical equipoise makes this difficult to justify. Comparison with current modalities would likely not be ethical/achievable on a like-for-like basis given MMS provides 100% margin assessment, enables histological clearance prior to reconstruction, and minimizes the removal of uninvolved tissue.
- Open Access
- 23 May 2022
- Published by Elsevier in JID Innovations
- Vol. 2 (5) , 100133
Detecting Eczema Areas in Digital Images: An Impossible Task?
- 23 May 2022
- Published by Elsevier in JID Innovations
- Vol. 2 (5) , 100133
Open AccessDetecting Eczema Areas in Digital Images: An Impossible Task?
- Open Access
- 3 June 2021
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 46 (7) , 1205-1210
What’s new in atopic eczema? An analysis of systematic reviews published in 2019. Part 1: Risk factors and prevention
This review is part of an annual evidence update on atopic eczema (AE), providing a summary of key findings from 18 systematic reviews published in 2019 on AE risk factors and prevention. Parental atopy, particularly AE, is a risk factor for offspring AE, and this risk is augmented by the number of parental atopic diseases present and the number of affected parents. Low quality evidence suggests autumn or winter birth increases childhood AE risk compared with birth in spring. There is some evidence to support filaggrin gene-environment interactions, however this is limited by small underpowered studies. There is no evidence to suggest that polymorphisms in the -1082, -592, -819 loci of the interleukin-10 gene increase susceptibility to AE. There is no robust evidence to support a relationship between childhood AE development and yoghurt consumption in the first year of life, gut microbiota variants, prenatal or infantile paracetamol exposure, maternal antibiotic exposure or air pollution. Three systematic reviews investigated the effect of probiotics given during pregnancy or infancy; though low-quality evidence suggests benefits of combined probiotics, these studies are limited by significant heterogeneity. No relationship between the age at which complementary food and beverages are introduced and the risk of developing AE in infancy was identified. Consistent evidence showed no relationship between human milk feeding and infant AE development, aside from limited evidence suggesting a protective role those with atopic heredity. This summary of recent evidence related to AE risk factors and prevention highlights the complex aetiology of AE.
- 3 June 2021
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 46 (7) , 1205-1210
Open AccessWhat’s new in atopic eczema? An analysis of systematic reviews published in 2019. Part 1: Risk factors and prevention
This review is part of an annual evidence update on atopic eczema (AE), providing a summary of key findings from 18 systematic reviews published in 2019 on AE risk factors and prevention. Parental atopy, particularly AE, is a risk factor for offspring AE, and this risk is augmented by the number of parental atopic diseases present and the number of affected parents. Low quality evidence suggests autumn or winter birth increases childhood AE risk compared with birth in spring. There is some evidence to support filaggrin gene-environment interactions, however this is limited by small underpowered studies. There is no evidence to suggest that polymorphisms in the -1082, -592, -819 loci of the interleukin-10 gene increase susceptibility to AE. There is no robust evidence to support a relationship between childhood AE development and yoghurt consumption in the first year of life, gut microbiota variants, prenatal or infantile paracetamol exposure, maternal antibiotic exposure or air pollution. Three systematic reviews investigated the effect of probiotics given during pregnancy or infancy; though low-quality evidence suggests benefits of combined probiotics, these studies are limited by significant heterogeneity. No relationship between the age at which complementary food and beverages are introduced and the risk of developing AE in infancy was identified. Consistent evidence showed no relationship between human milk feeding and infant AE development, aside from limited evidence suggesting a protective role those with atopic heredity. This summary of recent evidence related to AE risk factors and prevention highlights the complex aetiology of AE.